News

Press Releases

March 23, 2020
Verve Therapeutics’ CEO Sekar Kathiresan to Speak at Wall Street Journal Health Forum
October 3, 2019
Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer
October 2, 2019
Verve Therapeutics to Present at the 2019 Jefferies Gene Therapy/Editing Summit
September 16, 2019
Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board
May 7, 2019
Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV

Media Contact
Lisa Raffensperger
Ten Bridge Communications
(617) 903-8783

Presentations and Publications

See all

In the News

June 11, 2019
10-year-old’s cholesterol was over 800. Can CRISPR fix the problem?
The Philadelphia Inquirer
May 10, 2019
One-off injection may drastically reduce heart attack risk
The Guardian
May 7, 2019
With a superstar cardiologist as its CEO, new CRISPR company targets heart disease
STAT
May 7, 2019
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
Endpoints News
 

Stay Connected

Find us on LinkedIn and Twitter